An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 1115-1121

  Codullo, Veronica ^a,b   Baldwin, Helen M ^a   Singh, Mark D ^a   Fraser, Alasdair R ^a   Wilson, Catherine ^a   Gilmour, Ashley ^a   Hueber, Axel J ^a   Bonino, Claudia ^b   McInnes, Iain B ^a   Montecucco, Carlomaurizio ^b   Graham, Gerard J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR D6; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SYSTEMIC SCLEROSIS; THROMBOCYTE RICH PLASMA;

AGED; CASE-CONTROL STUDIES; CHEMOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; LIGANDS; MALE; MIDDLE AGED; RECEPTORS, CCR10; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; UP-REGULATION;

EID: 79955802032     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.137349     Document Type: Article

References (45)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009 ; 360 : 1989-2003.
2. Distler O, Matucci-Cerinic M, Müller-Ladner U, et al. A path to the future in scleroderma. Rheumatology (Oxford) 2008 ; 47 (Suppl 5) : v1.
3. Distler JH, Jüngel A, Caretto D, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006 ; 54 : 214-25. (Pubitemid 43122204) (Pubitemid 43122204)
4. Fukasawa C, Kawaguchi Y, Harigai M, et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003 ; 33 : 2792-800. (Pubitemid 37337145) (Pubitemid 37337145)
5. Yanaba K, Komura K, Kodera M, et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 2006 ; 65 : 124-6. (Pubitemid 41815654) (Pubitemid 41815654)
6. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004 ; 22 : 891-928. (Pubitemid 38680444) (Pubitemid 38680444)
7. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000 ; 12 : 121-7. (Pubitemid 30398626) (Pubitemid 30398626)
8. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999 ; 20 : 254-7. (Pubitemid 29258161) (Pubitemid 29258161)
9. Graham GJ. D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur J Immunol 2009 ; 39 : 342-51.
10. Graham GJ, McKimmie CS. Chemokine scavenging by D6: a movable feast? Trends Immunol 2006 ; 27 : 381-6. (Pubitemid 44038664) (Pubitemid 44038664)
11. Bonecchi R, Locati M, Galliera E, et al. Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol 2004 ; 172 : 4972-6. (Pubitemid 38456423) (Pubitemid 38456423)
12. Nibbs R, Graham G, Rot A. Chemokines on the move: control by the chemokine "interceptors" Duffy blood group antigen and D6. Semin Immunol 2003 ; 15 : 287-94. (Pubitemid 38156057) (Pubitemid 38156057)
13. Nibbs RJ, Wylie SM, Yang J, et al. Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem 1997 ; 272 : 32078-83. (Pubitemid 28011878) (Pubitemid 28011878)
14. Nibbs RJ, Kriehuber E, Ponath PD, et al. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001 ; 158 : 867-77. (Pubitemid 32221780) (Pubitemid 32221780)
15. Madigan J, Freeman DJ, Menzies F, et al. Chemokine scavenger D6 is expressed by trophoblasts and aids the survival of mouse embryos transferred into allogeneic recipients. J Immunol 2010 ; 184 : 3202-12.
16. Martinez de la Torre Y, Buracchi C, Borroni EM, et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 2007 ; 104 : 2319-24. (Pubitemid 46391395) (Pubitemid 46391395)
17. McKimmie CS, Fraser AR, Hansell C, et al. Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol 2008 ; 181 : 3353-63.
18. Fra AM, Locati M, Otero K, et al. Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol 2003 ; 170 : 2279-82. (Pubitemid 36245612) (Pubitemid 36245612)
19. Weber M, Blair E, Simpson CV, et al. The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol Biol Cell 2004 ; 15 : 2492-508. (Pubitemid 38580663) (Pubitemid 38580663)
20. Jamieson T, Cook DN, Nibbs RJ, et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 2005 ; 6 : 403-11. (Pubitemid 41716781) (Pubitemid 41716781)
21. Martinez de la Torre Y, Locati M, Buracchi C, et al. Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur J Immunol 2005 ; 35 : 1342-6. (Pubitemid 40691415) (Pubitemid 40691415)
22. Nibbs RJ, Gilchrist DS, King V, et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 2007 ; 117 : 1884-92. (Pubitemid 47036322) (Pubitemid 47036322)
23. Bordon Y, Hansell CA, Sester DP, et al. The atypical chemokine receptor D6 contributes to the development of experimental colitis. J Immunol 2009 ; 182 : 5032-40.
24. Vetrano S, Borroni EM, Sarukhan A, et al. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut 2010 ; 59 : 197-206.
25. Whitehead GS, Wang T, DeGraff LM, et al. The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity. Am J Respir Crit Care Med 2007 ; 175 : 243-9. (Pubitemid 46203127) (Pubitemid 46203127)
26. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 ; 15 : 202-5. (Pubitemid 18073738) (Pubitemid 18073738)
27. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001 ; 28 : 1573-6.
28. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003 ; 21 ( 3 Suppl 29 ): S39-41.
29. Medsger TA Jr, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003 ; 21 ( 3 Suppl 29 ): S42-6.
30. Blackburn PE, Simpson CV, Nibbs RJ, et al. Purification and biochemical characterization of the D6 chemokine receptor. Biochem J 2004 ; 379 : 263-72. (Pubitemid 38570098) (Pubitemid 38570098)
31. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007 ; 19 : 574-9. (Pubitemid 47530878) (Pubitemid 47530878)
32. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008 ; 48 : 171-97. (Pubitemid 351756361) (Pubitemid 351756361)
33. Distler JH, Akhmetshina A, Schett G, et al. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009 ; 48 : 98-103.
34. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001 ; 44 : 2665-78. (Pubitemid 33049344) (Pubitemid 33049344)
35. Galindo M, Santiago B, Rivero M, et al. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001 ; 44 : 1382-6. (Pubitemid 32537537) (Pubitemid 32537537)
36. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP- 1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999 ; 117 : 159-65. (Pubitemid 29292792) (Pubitemid 29292792)
37. Yamamoto T, Eckes B, Hartmann K, et al. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001 ; 26 : 133-9. (Pubitemid 32510721) (Pubitemid 32510721)
38. Carulli MT, Handler C, Coghlan JG, et al. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann Rheum Dis 2008 ; 67 : 105-9.
39. Karrer S, Bosserhoff AK, Weiderer P, et al. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005 ; 124 : 92-8. (Pubitemid 40100953) (Pubitemid 40100953)
40. Radstake TR, Vonk MC, Dekkers M, et al. The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: results from a multicenter study of European Caucasian patients. Hum Immunol 2009 ; 70 : 130-3.
41. Lee EB, Zhao J, Kim JY, et al. Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum 2007 ; 56 : 2443-8. (Pubitemid 47173592) (Pubitemid 47173592)
42. Antonelli A, Ferri C, Fallahi P, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 2008 ; 47 : 45-9. (Pubitemid 350286260) (Pubitemid 350286260)
43. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev 2005 ; 16 : 687-94. (Pubitemid 41505524) (Pubitemid 41505524)
44. Neote K, Mak JY, Kolakowski LF Jr, et al. Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 1994 ; 84 : 44-52. (Pubitemid 24193803) (Pubitemid 24193803)
45. Meloni F, Solari N, Cavagna L, et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol 2009 ; 27 : 765-72.